Products

Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.

Connect With Us

Immunotherapy (Investigational) (16)

Quick filters: Solid Tumour Hematologic Both Name A-Z Name Z-A

Therapeutic Areas

Sort by

Clear all filters

Molecule	Drug Class / Mechanism	Oncology Type
Magrolimab	CD47 (Macrophage Checkpoint) Inhibitor	Hematologic
Molecule Magrolimab Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Evorpacept	CD47 (Macrophage Checkpoint) Inhibitor	Hematologic
Molecule Evorpacept Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Lemzoparlimab	CD47 (Macrophage Checkpoint) Inhibitor	Hematologic
Molecule Lemzoparlimab Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Letaplimab	CD47 (Macrophage Checkpoint) Inhibitor	Hematologic
Molecule Letaplimab Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
IBI322 (CD47/PD-L1)	CD47 (Macrophage Checkpoint) Inhibitor	Hematologic
Molecule IBI322 (CD47/PD-L1) Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
TTI-621 (Cibisatamab-related)	CD47 (Macrophage Checkpoint) Inhibitor	Hematologic
Molecule TTI-621 (Cibisatamab-related) Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Cibisatamab	CD47 (Macrophage Checkpoint) Inhibitor	Hematologic
Molecule Cibisatamab Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Tarlatamab	Costimulatory / Bispecific Agent	Solid Tumour
Molecule Tarlatamab Therapeutic Category Immunotherapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Costimulatory / Bispecific Agent
Ivonescimab	Costimulatory / Bispecific Agent	Solid Tumour
Molecule Ivonescimab Therapeutic Category Immunotherapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Costimulatory / Bispecific Agent
Vopratelimab	Costimulatory / Bispecific Agent	Solid Tumour
Molecule Vopratelimab Therapeutic Category Immunotherapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Costimulatory / Bispecific Agent
Utomilumab	Costimulatory / Bispecific Agent	Solid Tumour
Molecule Utomilumab Therapeutic Category Immunotherapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Costimulatory / Bispecific Agent
Urelumab	Costimulatory / Bispecific Agent	Solid Tumour
Molecule Urelumab Therapeutic Category Immunotherapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Costimulatory / Bispecific Agent

Magrolimab Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Evorpacept Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Lemzoparlimab Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Letaplimab Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
IBI322 (CD47/PD-L1) Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
TTI-621 (Cibisatamab-related) Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Cibisatamab Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Tarlatamab Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Costimulatory / Bispecific Agent
Ivonescimab Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Costimulatory / Bispecific Agent
Vopratelimab Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Costimulatory / Bispecific Agent
Utomilumab Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Costimulatory / Bispecific Agent
Urelumab Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Costimulatory / Bispecific Agent

‹ 1 2 ›

Product Range

Company

Global Network

Products

Magrolimab

Evorpacept

Lemzoparlimab

Letaplimab

IBI322 (CD47/PD-L1)

TTI-621 (Cibisatamab-related)

Cibisatamab

Tarlatamab

Ivonescimab

Vopratelimab

Utomilumab

Urelumab

Magrolimab

Evorpacept

Lemzoparlimab

Letaplimab

IBI322 (CD47/PD-L1)

TTI-621 (Cibisatamab-related)

Cibisatamab

Tarlatamab

Ivonescimab

Vopratelimab

Utomilumab

Urelumab